.H. Summia Parveen
Research Subjects
.H. Summia Parveen has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- G. Sathish Kumar
Department of Artificial Intelligence and Data Science, Sri Eshwar College of Engineering, Coimbatore, India
1 shared publication - P. Parthasarathi
Department of Computer Science and Engineering, Bannari Amman Institute of Technology, Sathyamangalam, Erode, Tamil Nadu, India
1 shared publication - Paramasivam Muthan Eswaran
Sona College of Technology
1 shared publication - Uma Shankari Srinivasan
Associate Professor, Department of Computer Science and Applications, SRM Institute of Science and Technology, Ramapuram Campus, Chennai, India
1 shared publication
Latest Publications
- Open Access
- 29 June 2026
- Published by International Academic Institute for Science and Technology in International Academic Journal of Innovative Research
- Vol. 13 (2) , 42-49
Advances in Biotechnology for Developing Personalized Medicine Approaches in Clinical Practice
Personalized medicine has recently emerged as a revolutionary clinical paradigm that enables individualized disease prevention, diagnosis, and treatment guided by a patient's genetic, molecular, and clinical factors. While much progress has been made in applying biotechnology to realize the goals of personalized care, issues of inter-patient heterogeneity, the time lag in biomarker discovery, and the inadequacies of existing one-size-fits-all medical paradigms still undermine clinical benefit. In this study, we have examined current advances in applying biotechnology to developing clinical approaches for personalized medicine. This process integrates genomic profiling, molecular diagnostics, biomarker identification, patient stratification, and treatment selection into a single framework. We utilized 520 patient profiles from categories spanning oncology, cardiovascular diseases, neurological disorders, metabolic syndromes, and inherited diseases, and applied a structured analysis approach. Comparing the diagnostic effectiveness of the developed framework with a standard clinical protocol for disease intervention in a clinical evaluation study showed that the classification accuracy, sensitivity, and specificity of the patient characterization protocol within the biotechnology-driven framework were 94.6%, 91.8%, and 93.4%, respectively. The treatment recommendation model developed using the biomarker discovery framework achieved a drug-matching rate of 93.2%, while 87.5% of patient populations achieved clinical efficacy post-biomarker-directed therapeutic intervention. In addition, improvements of 18.7%, 16.4%, and 24.5%, and a reduction of 21.3% were observed in diagnostic accuracy, drug treatment selection efficiency, clinical treatment efficacy, and adverse drug reactions, respectively, compared with conventional clinical protocols. Our study suggests that integrating genetics and molecular analytics into precision medicine contributes to more precise diagnoses, more precise treatment decisions, and more effective therapy selection for individual patients, and will help realize its large-scale implementation as part of the next generation of clinical systems.
- 29 June 2026
- Published by International Academic Institute for Science and Technology in International Academic Journal of Innovative Research
- Vol. 13 (2) , 42-49
Open AccessAdvances in Biotechnology for Developing Personalized Medicine Approaches in Clinical Practice
Personalized medicine has recently emerged as a revolutionary clinical paradigm that enables individualized disease prevention, diagnosis, and treatment guided by a patient's genetic, molecular, and clinical factors. While much progress has been made in applying biotechnology to realize the goals of personalized care, issues of inter-patient heterogeneity, the time lag in biomarker discovery, and the inadequacies of existing one-size-fits-all medical paradigms still undermine clinical benefit. In this study, we have examined current advances in applying biotechnology to developing clinical approaches for personalized medicine. This process integrates genomic profiling, molecular diagnostics, biomarker identification, patient stratification, and treatment selection into a single framework. We utilized 520 patient profiles from categories spanning oncology, cardiovascular diseases, neurological disorders, metabolic syndromes, and inherited diseases, and applied a structured analysis approach. Comparing the diagnostic effectiveness of the developed framework with a standard clinical protocol for disease intervention in a clinical evaluation study showed that the classification accuracy, sensitivity, and specificity of the patient characterization protocol within the biotechnology-driven framework were 94.6%, 91.8%, and 93.4%, respectively. The treatment recommendation model developed using the biomarker discovery framework achieved a drug-matching rate of 93.2%, while 87.5% of patient populations achieved clinical efficacy post-biomarker-directed therapeutic intervention. In addition, improvements of 18.7%, 16.4%, and 24.5%, and a reduction of 21.3% were observed in diagnostic accuracy, drug treatment selection efficiency, clinical treatment efficacy, and adverse drug reactions, respectively, compared with conventional clinical protocols. Our study suggests that integrating genetics and molecular analytics into precision medicine contributes to more precise diagnoses, more precise treatment decisions, and more effective therapy selection for individual patients, and will help realize its large-scale implementation as part of the next generation of clinical systems.